Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Research analysts at HC Wainwright upped their FY2028 EPS estimates for Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.60 per share for the year, up from their prior forecast of $0.58. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share.
Separately, Raymond James lifted their price target on Oncolytics Biotech from C$3.00 to C$3.50 in a research note on Friday, September 20th.
Get Our Latest Research Report on ONC
Oncolytics Biotech Price Performance
TSE ONC traded down C$0.03 on Friday, reaching C$1.38. The company's stock had a trading volume of 95,231 shares, compared to its average volume of 71,027. The firm's 50 day moving average is C$1.50 and its two-hundred day moving average is C$1.45. The stock has a market cap of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. Oncolytics Biotech has a twelve month low of C$1.15 and a twelve month high of C$2.32.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
